The use of AI in glaucoma with I. Paul Singh, MD

I. Paul Singh, MD, an anterior segment and glaucoma specialist, attended the Glaucoma 360 conference in 2025. He participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.

Singh explained that AI is already being used in various aspects of glaucoma management, from diagnostics and treatment planning to patient outreach and research operations. Singh noted that AI can help doctors efficiently analyze the large amounts of data collected during patient visits, such as visual fields, OCT scans, and medical history. This allows clinicians to better identify patients at risk of rapid disease progression and tailor treatment accordingly. He also discussed how AI can support research centers by automating certain protocols and operational tasks.

In addition to the AI panel, Singh also spoke about advancements in drug delivery for glaucoma. He highlighted recently approved products as well as upcoming technologies utilizing intraocular lenses, suprachoroidal space, and intravitreal approaches. Singh explained that these drug delivery systems address the challenge of patient compliance, which is a major factor in glaucoma management.

Singh emphasized the shift towards an "interventional glaucoma mindset" that combines various treatment modalities, including drug delivery, minimally invasive glaucoma surgeries, and selective laser trabeculoplasty. He believes this multifaceted approach can help maximize quality of life and minimize progression in glaucoma patients.

Looking to the future, Singh acknowledged the growing glaucoma patient population and the need for more efficient care models. He suggested using advanced diagnostics and triaging systems to determine appropriate treatment intensity and follow-up frequency for each individual. He shared that his is excited about the potential to not only neuroprotect, but also potentially restore vision in glaucoma patients through emerging therapies.